Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Xeris Biopharma Holdings (XERS) Accumulated Depreciation & Amortization (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 7.01% year-over-year to $1.3 million, compared with a TTM value of $1.3 million through Dec 2025, up 7.01%, and an annual FY2025 reading of $1.3 million, up 7.01% over the prior year.
  • Accumulated Depreciation & Amortization was $1.3 million for Q4 2025 at Xeris Biopharma Holdings, up from $978000.0 in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $1.5 million in Q4 2023 and bottomed at $315000.0 in Q1 2025.
  • Average Accumulated Depreciation & Amortization over 5 years is $839600.0, with a median of $832000.0 recorded in 2023.
  • The sharpest move saw Accumulated Depreciation & Amortization increased 13.4% in 2023, then decreased 19.89% in 2024.
  • Year by year, Accumulated Depreciation & Amortization stood at $1.3 million in 2021, then increased by 5.34% to $1.4 million in 2022, then grew by 6.21% to $1.5 million in 2023, then dropped by 17.48% to $1.2 million in 2024, then rose by 7.01% to $1.3 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for XERS at $1.3 million in Q4 2025, $978000.0 in Q3 2025, and $640000.0 in Q2 2025.